Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2008; 51:818-825, doi:10.1016/j.jacc.2007.11.035
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Current Clinical Collection-Atrial Fibrillation
Right arrow View Genuine Article Video Part Two
Right arrow View CVN News Brief
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (28)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ruiz-Nodar, J. M.
Right arrow Articles by Lip, G. Y.H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ruiz-Nodar, J. M.
Right arrow Articles by Lip, G. Y.H.
Related Collections
Right arrowRelated Articles

FOCUS ISSUE: ATRIAL FIBRILLATION: CLINICAL RESEARCH: ATRIAL FIBRILLATION AND EMBOLISM

Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation

Implications for Bleeding Risk and Prognosis

Juan M. Ruiz-Nodar, MD, PhD*, Francisco Marín, MD, PhD{dagger},{ddagger}, José Antonio Hurtado, MD{dagger},{ddagger}, José Valencia, MD, PhD*, Eduardo Pinar, MD, PhD{dagger},{ddagger}, Javier Pineda, MD, PhD*, Juan Ramón Gimeno, MD, PhD{dagger},{ddagger}, Francisco Sogorb, MD, PhD*, Mariano Valdés, MD, PhD{dagger} and Gregory Y.H. Lip, MD, FACC, FESC§,*

* Department of Cardiology, Hospital General Universitario de Alicante, Alicante, Spain
{dagger} Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
{ddagger} Red de Investigación Cardiovascular RECAVA, Instituto Salud Carlos III, Madrid, Spain
§ University Department of Medicine, City Hospital, Birmingham, United Kingdom.

Manuscript received August 20, 2007; revised manuscript received October 29, 2007, accepted November 20, 2007.

* Reprint requests and correspondence: Dr. Gregory Y. H. Lip, University Department of Medicine, City Hospital, Birmingham B18 7QH, United Kingdom. (Email: g.y.h.lip{at}bham.ac.uk).

Objectives: This study was designed to review outcomes in relation to antithrombotic therapy management strategies for patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI) with stenting.

Background: There is limited evidence on the optimal antithrombotic therapy management strategies for patients with AF who undergo PCI with stenting.

Methods: We reviewed 426 patients (70.9% men, mean age 71.5 ± 8.5 years) with AF undergoing PCI with stenting between 2001 and 2006. We recorded clinical and demographic characteristics of the patients, stroke risk factors, and antithrombotic therapy use before PCI and at discharge. Clinical follow-up was performed, and all bleeding episodes, thromboembolism, and major adverse cardiac events (MACE) (i.e., death, acute myocardial infarction, or target lesion revascularization) were recorded.

Results: The most commonly associated comorbidities were hypertension (74.5%), diabetes mellitus (40.2%), chronic renal failure (14.9%), and congestive heart failure (26.7%); 80% of patients had ≥2 stroke risk factors. Of the drugs prescribed at discharge, aspirin plus clopidogrel were used in 174 patients (40.8%), whereas 213 patients (50%) were discharged with triple therapy (coumarins, aspirin, and clopidogrel). Complete follow-up was achieved in 87.5% (median 594 days; range 0 to 2,190). The incidence of adverse events was high (36.6%), with major bleeding in 12.3%, thromboembolic events in 4.2%, and MACE in 32.3%. All-cause mortality was high (22.6%). In a multivariate analysis, non-anticoagulation with coumarins increased mortality (17.8% vs. 27.8%; hazard ratio [HR] = 3.43; 95% confidence interval [CI] 1.61 to 7.54; p = 0.002) and MACE (26.5% vs. 38.7%; HR = 4.9; 95% CI 2.17 to 11.1; p < 0.01) In a Cox-regression analysis, non-anticoagulation (p < 0.01) and age (p = 0.02) were independent predictors of MACE.

Conclusions: Patients with AF undergoing PCI with stenting represent a high-risk population because of age, comorbidities, and presence of stroke risk factors. These patients have a high mortality and MACE rate, which is reduced by anticoagulation therapy.

Abbreviations and Acronyms
  ACS = acute coronary syndrome
  AF = atrial fibrillation
  DES = drug-eluting stent(s)
  MACE = major adverse cardiac events
  MAE = major adverse events
  PCI = percutaneous coronary intervention


Related Articles

"Triple Therapy" or Triple Threat?: Balancing the Risks of Antithrombotic Therapy for Patients With Atrial Fibrillation and Coronary Stents
Steven Francescone and Jonathan L. Halperin
J. Am. Coll. Cardiol. 2008 51: 826-827. [Full Text] [PDF]

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 51: A23-A24. [Full Text] [PDF]



This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
J. P. Piccini, A. F. Hernandez, X. Zhao, M. R. Patel, W. R. Lewis, E. D. Peterson, G. C. Fonarow, and Get With The Guidelines Steering Committee and Hos
Quality of care for atrial fibrillation among patients hospitalized for heart failure.
J. Am. Coll. Cardiol., September 29, 2009; 54(14): 1280 - 1289.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
A Sambola, I Ferreira-Gonzalez, J Angel, F Alfonso, J Maristany, O Rodriguez, H Bueno, J R Lopez-Minguez, J Zueco, F Fernandez-Aviles, et al.
Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study
Heart, September 15, 2009; 95(18): 1483 - 1488.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
R. D. Lopes, L. E. Elliott, H. D. White, J. S. Hochman, F. Van de Werf, D. Ardissino, T. T. Nielsen, W. D. Weaver, P. Widimsky, P. W. Armstrong, et al.
Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial
Eur. Heart J., August 2, 2009; 30(16): 2019 - 2028.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
A. Schomig, N. Sarafoff, and M. Seyfarth
Triple antithrombotic management after stent implantation: when and how?
Heart, August 1, 2009; 95(15): 1280 - 1285.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. R. Holmes Jr, D. J. Kereiakes, N. S. Kleiman, D. J. Moliterno, G. Patti, and C. L. Grines
Combining Antiplatelet and Anticoagulant Therapies.
J. Am. Coll. Cardiol., July 7, 2009; 54(2): 95 - 109.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
F. Marin, P. Kirchhof, and G. Y.H. Lip
Antithrombotic therapy use for patients with atrial fibrillation undergoing percutaneous coronary intervention: new data in an area of limited evidence
Europace, July 1, 2009; 11(7): 842 - 843.
[Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
M. A. Crandall, D. J. Bradley, D. L. Packer, and S. J. Asirvatham
Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies
Mayo Clin. Proc., July 1, 2009; 84(7): 643 - 662.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
APPRAISE Steering Committee and Investigators
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial
Circulation, June 9, 2009; 119(22): 2877 - 2885.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
A. Prasad and D. R Holmes
Update on dual antiplatelet therapy for percutaneous coronary intervention
Heart, June 1, 2009; 95(11): 861 - 865.
[Full Text] [PDF]


Home page
Eur Heart JHome page
J. Schmitt, G. Duray, B. J. Gersh, and S. H. Hohnloser
Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications
Eur. Heart J., May 1, 2009; 30(9): 1038 - 1045.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. M. Ruiz-Nodar, F. Marin, J. Sanchez-Paya, J. A. Hurtado, J. Valencia-Martin, S. Manzano-Fernandez, V. Roldan, V. Perez-Andreu, F. Sogorb, M. Valdes, et al.
Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation
Eur. Heart J., April 2, 2009; 30(8): 932 - 939.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
S. Koul and D. J. Moliterno
Bare-Metal Versus Drug-Eluting Stent Placement Among Patients Presenting With Anemia
J. Am. Coll. Cardiol. Intv., April 1, 2009; 2(4): 337 - 338.
[Full Text] [PDF]


Home page
ChestHome page
S. Manzano-Fernandez, F. Marin, F. J. Pastor-Perez, C. Caro, F. Cambronero, J. Lacunza, E. Pinar, D. A. Pascual-Figal, M. Valdes, and G. Y. H. Lip
Impact of Chronic Kidney Disease on Major Bleeding Complications and Mortality in Patients With Indication for Oral Anticoagulation Undergoing Coronary Stenting
Chest, April 1, 2009; 135(4): 983 - 990.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Sourgounis, J. Lipiecki, T. S. Lo, and M. Hamon
Coronary Stents and Chronic Anticoagulation
Circulation, March 31, 2009; 119(12): 1682 - 1688.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al.
Highlights of the Year in JACC 2008.
J. Am. Coll. Cardiol., January 27, 2009; 53(4): 373 - 398.
[Full Text] [PDF]


Home page
ESC Textbook of Cardiovascular MedicineHome page
A. J. Camm, P. Kirchhof, G. Y.H. Lip, I. Savelieva, and S. Ernst
CHAPTER 29 Atrial Fibrillation
ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
T. Ohmori, Y. Yano, K. Shimada, K. Kario, and Y. Sakata
Is thrombogenesis related to residual platelet function in ischaemic heart disease?: reply
Eur. Heart J., December 2, 2008; 29(24): 3065 - 3066.
[Full Text] [PDF]


Home page
BMJHome page
G. Y H Lip
Managing the anticoagulated patient with atrial fibrillation at high risk of stroke who needs coronary intervention
BMJ, September 12, 2008; 337(sep12_1): a840 - a840.
[Full Text]


Home page
ChestHome page
S. Manzano-Fernandez, F. J. Pastor, F. Marin, F. Cambronero, C. Caro, D. A. Pascual-Figal, I. P. Garrido, E. Pinar, M. Valdes, and G. Y. H. Lip
Increased Major Bleeding Complications Related to Triple Antithrombotic Therapy Usage in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Artery Stenting
Chest, September 1, 2008; 134(3): 559 - 567.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
S. H. Hohnloser, G. Z. Duray, U. Baber, and J. L. Halperin
Prevention of stroke in patients with atrial fibrillation: current strategies and future directions
Eur. Heart J. Suppl., September 1, 2008; 10(suppl_H): H4 - H10.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
J. M. Ruiz-Nodar, F. Marin, and G. Y.H. Lip
Antithrombotic Therapy Use After Percutaneous Coronary Intervention and Stent Implantation in Patients Taking Chronic Oral Anticoagulation
J. Am. Coll. Cardiol. Intv., June 1, 2008; 1(3): 329 - 329.
[Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
R. Rogacka, A. Chieffo, and A. Colombo
Reply
J. Am. Coll. Cardiol. Intv., June 1, 2008; 1(3): 330 - 331.
[Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
A J. Hermosillo and S. A Spinler
Aspirin, Clopidogrel, and Warfarin: Is the Combination Appropriate and Effective or Inappropriate and Too Dangerous?
Ann. Pharmacother., June 1, 2008; 42(6): 790 - 805.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Francescone and J. L. Halperin
"Triple Therapy" or Triple Threat?: Balancing the Risks of Antithrombotic Therapy for Patients With Atrial Fibrillation and Coronary Stents
J. Am. Coll. Cardiol., February 26, 2008; 51(8): 826 - 827.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement